Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

Humans have appreciated the beauty of flowers for centuries. Yet, flowers aren't just aesthetically pleasing. They also play ...

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...

Cardiac arrhythmias affect millions across the world and are responsible for a fifth of all deaths in the Netherlands.

Cell and gene therapy tout promising results, but manufacturing challenges around personalized treatments require industry ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...